Skip to main content
Clinical Trials/ISRCTN54191675
ISRCTN54191675CompletedPhase 3

Study of Peri-Articular Anaesthetic for Replacement of the Knee. The clinical and cost effectiveness of peri-articular liposomal bupivacaine compared with bupivacaine hydrochloride for post-operative recovery after knee replacement surgery: A multi-centre, blinded, randomised controlled trial

niversity of Leeds0 sites533 target enrollmentStarted: November 14, 2017Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
533

Study Overview

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31842977 protocol (added 18/12/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35385072/ (added 07/04/2022)

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Current participant inclusion criteria as of 11/01/2019:
  • 1. Unilateral primary knee replacement, including both total knee replacement (TKR) and unicompartmental knee replacement (UKR), for end-stage osteoarthritis
  • 2. American Society of Anaesthesiologists (ASA) Grade I to III
  • 3. Participant is willing and able to consent for themselves
  • 4. Male or female, aged 18 years or above
  • 5. In the Investigator’s opinion, is able and willing to comply with all trial requirements
  • Previous participant inclusion criteria as of 26/10/2018:
  • 1. Unilateral primary knee replacement, including both total knee replacement (TKR) or unicompartmental knee replacement (UKR), for end stage osteoarthritis
  • 2. Willing and able consent for themselves
  • 3. Male or female, aged 18 years or above
  • 4. In the Investigator’s opinion, is able and willing to comply with all trial requirements.
  • Previous participant inclusion criteria:
  • 1. Participant is willing and able consent for themselves
  • 2. Male or Female, aged 18 years or above
  • 3. End stage osteoarthritis of the knee
  • 4. In the Investigator’s opinion, is able and willing to comply with all trial requirements

Exclusion Criteria

  • Current participant exclusion criteria as of 11/01/2019:
  • 1. Allergy or intolerance to amide-type local anaesthetics
  • 2. Objective evidence of nerve damage in the affected lower limb
  • 3. Rheumatoid arthritis
  • 4. Any other significant disease, disorder or condition which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the results of the trial, or the participant’s ability to participate in the trial
  • 5. Participants who have participated in another research trial involving an investigational product in the past 6 months
  • 6. Participants who have significant cognitive impairment or language issues
  • 7. Contra-lateral knee replacement within the trial or within 12 months prior to randomization
  • Previous participant exclusion criteria as of 26/10/2018:
  • 1. American Society of Anaesthesiologists (ASA) Grade III or above
  • 2. Allergy or intolerance to amide type local anaesthetics
  • 3. Objective evidence of nerve damage in the affected lower limb
  • 4. Rheumatoid arthritis
  • 5. Any other significant disease, disorder or condition which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the results of the trial, or the participant’s ability to participate in the trial
  • 6. Participants who have participated in another research trial involving an investigational product in the past 6 months
  • 7. Participants who have significant cognitive impairment or language issues
  • 8. Contra-lateral knee replacement within the trial or within 12 months prior to randomisation
  • Previous participant exclusion criteria:
  • 1. American Society of Anaesthesiologists (ASA) Grade III or above
  • 2. Allergy or intolerance to amide type local anaesthetics
  • 3. Objective evidence of nerve damage in the affected lower limb
  • 4. Rheumatoid arthritis
  • 5. Any other significant disease, disorder or condition which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
  • 6. Participants who have participated in another research trial involving an investigational product in the past 6 months
  • 7. Participants who have significant cognitive impairment or language issues
  • 8. Contra-lateral knee replacement (If the patient is receiving staged bilateral knees, they may still participate in the trial but data will only be included from the first knee)

Investigators

Sponsor
niversity of Leeds

Similar Trials